MasaomiNangaku TokyoJapan

Wcn26 Post edited Speaker Card

29 March 2026

Time	Session

8:10 a.m. 9:10 a.m.	Industry Symposium 1 MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan Advanced Data Science in CKD Management YuichiroYano Speaker y.yano@juntendo.ac.jpJapan An Integrated Approach to Cardio-Renal-Metabolic Disorders : Addressing Hypertension and Dyslipidemia KOUICHITAMURA Speaker tamukou@yokohama-cu.ac.jpJapan 315
3:50 p.m. 4:50 p.m.	Innovating Kidney Trials: PROMs, New Designs, and Global Roadmaps MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan Opening & Session Overview AdeeraLevin Speaker alevin@providencehealth.bc.caCanada Overcoming the Bottleneck- Endpoints in Phase 2 Trials Kai-UweEckardt Speaker kai-uwe.eckardt@charite.deGermany Integrating Patient-Reported Outcomes (PROMs) AllisonJaure Speaker allison.jaure@sydney.edu.auAustralia Innovating with New Trial Designs MegJardine Speaker meg.jardine@sydney.edu.auAustralia Using Hierarchical Composite Endpoints (HCEs) HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands Panel Discussion & Q&A Closing Remarks MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan 311 - 312

30 March 2026

Time	Session

8:10 a.m. 9:10 a.m.	Industry Symposium 35 KatherineTuttle Chair Katherine.Tuttle@providence.orgUnited States Mechanistic Effects of Semaglutide on Kidney Disease in Type 2 Diabetes: The REMODEL trial KatherineTuttle Speaker Katherine.Tuttle@providence.orgUnited States Multiparametric Imaging and Tissue Transcriptomics to Unravel Mechanisms of Kidney Protection MatthiasKretzler Speaker kretzler@umich.eduUnited States GLP1s in Combination With Other Therapies and Applications in Clinical Practice BrendonNeuen Speaker bneuen@georgeinstitute.org.auAustralia The Future of GLP1s and Other Incretin-based Therapies for Kidney Disease MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan 301 - 302
9:25 a.m. 10:55 a.m.	Integrating Care for Cardiovascular-Kidney-Metabolic Health Across the Lifespan IK Is Kidney Dysfunction in Heart Failure More Than Just Low Cardiac Output? BrendonNeuen Speaker bneuen@georgeinstitute.org.auAustralia Is Metabolic Dysfunction in Cardiovascular-Kidney-Metabolic Syndrome More Than Just Hyperglycemia and Obesity? HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands Kidney at the Center of Conservative Kidney Management Syndrome MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan What’s Next in Cardiovascular-Kidney-Metabolic Therapy? RobertoPecoits-Filho Speaker roberto.pecoits@arborresearch.orgUnited States Q&A 501 - 502	HIT! High Impact Clinical Trials 4 KeiFukami Chair fukami@med.kurume-u.ac.jpJapan LizLightstone Chair l.lightstone@imperial.ac.ukUnited Kingdom MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan Effect of a 12-week Intradialytic Cycling Intervention on Hemodialysis-induced Myocardial Stunning: A Multi-centre Randomized Controlled Trial (Tickers_hd) ClaraBohm Speaker cbohm@sogh.mb.caCanada Effect of Finerenone on Circulating Biomarkers: A Confidence Analysis MarioBerger Speaker mario.berger@bayer.comGermany Effect of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-creatinine Ratio by Age and Sex in the Confidence Trial RajivAgarwal Speaker ragarwal@iu.eduUnited States Estimated Glomerular Filtration Rate, Systolic Blood Pressure, and Urinary Albumin-to-creatinine Ratio — Unravelling the Interplay in Combination: Findings From the CONFIDENCE Trial RajivAgarwal Speaker ragarwal@iu.eduUnited States Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double Blind Randomized Controlled Trial Naya Huang Speaker huangnaya@163.comChina Main Hall
12:50 p.m. 1:50 p.m.	Industry Symposium 45 MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan Welcome & Introductions MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan UACR: Hidden Marker of Heart and Kidney Risk PamKushner Speaker pamkushner@hotmail.comUnited States RobertoPecoits-Filho Speaker roberto.pecoits@arborresearch.orgUnited States The Impact of RAAS Dysregulation in Cardiorenal Disease Sydney Tang Speaker scwtang@hku.hkHong Kong, China 304
3:50 p.m. 4:50 p.m.	The Global Kidney Health Atlas: Advancing Equity and Excellence in Kidney Care Worldwide Opening & Session Introduction AdeeraLevin Chair alevin@providencehealth.bc.caCanada Global Overview: The ISN-Global Kidney Health Atlas 2025 Update SomkanyaTungsanga Speaker s.tungsanga@gmail.comCanada Regional Perspectives: Gaps and Successes in Kidney Care Delivery ArpanaIyengar Speaker arpanaiyengar@gmail.comIndia Innovation & Collaboration for Better Kidney Health AminuBello Speaker aminu1@ualberta.caCanada Future Directions Q&A & Closing MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan 303
5 p.m. 6 p.m.	Industry Symposium 57 MasaomiNangaku Chair mnangaku@m.u-tokyo.ac.jpJapan The Future of Lupus Nephritis: Achieving Renal Protection Through Proteinuria Control ShoichiMaruyama Speaker marus@med.nagoya-u.ac.jpJapan A New Era in Lupus Nephritis: Clinical Evidence and Therapeutic Positioning of Triple Therapy KeijuHiromura Speaker hiomura@gunma-u.ac.jpJapan 304